MicroRNAs - Promising Biomarkers for Monitoring Progression of Multiple Sclerosis

by Dr. Trupti Shirole on  January 24, 2017 at 10:37 AM Research News
RSS Email Print This Page Comment bookmark
Font : A-A+

Multiple sclerosis (MS) is a demyelinating disease in which in which the immune system eats away the protective insulating covering of nerves cells in the brain and spinal cord.
 MicroRNAs - Promising Biomarkers for Monitoring Progression of Multiple Sclerosis
MicroRNAs - Promising Biomarkers for Monitoring Progression of Multiple Sclerosis

MicroRNAs are small RNA molecules that influence basic cellular processes and have been proposed as biomarkers for the diagnosis, progression and treatment of multiple sclerosis.

In a new study conducted at the Ann Romney Center of Neurologic Diseases at Brigham and Women's Hospital, researchers have found that serum microRNAs are linked to MRI findings in the brain and spinal cord in patients with MS.

These findings suggest that microRNAs could serve as promising biomarkers for monitoring the progression of MS and could help to identify distinct underlying disease processes, such as inflammation and tissue destruction. The study was published in JAMA Neurology.

In a large study, researchers examined the connection between serum microRNAs and MRI measures to evaluate the severity of MS, which included looking at lesions and atrophy, a measure of degeneration of the cells, in the central nervous system. Among the findings, the researchers identified that the expression of certain microRNAs were linked to MRI measures.

The authors showed that these associations could be protective or harmful to patients (depending upon the function of the microRNA). They also found that different mechanisms were linked to different locations of MS changes, such as in the brain or spinal cord. Additionally, the study suggested certain sets of microRNAs were linked to lesions, while others were linked to atrophy, which is known to cause more devastating effects to MS patients.

"These findings tell us the disease is heterogeneous. There's a complex set of mechanisms at play, and it may vary from patient to patient," says senior co-author Rohit Bakshi. "Another implication of this research is that it could eventually lead to us having a blood test to identify the subtype of MS in a patient, to help guide therapeutic decisions and prognosis," says Bakshi, also a neurologist at BWH.

"MicroRNAs could serve as biomarkers of the underlying MS disease processes, once validated and standardized for clinical settings. In addition, these markers have the potential to provide novel treatment targets," says Roopali Gandhi, senior co-author and an assistant professor at BWH.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

Recommended Reading

More News on:

Chemotherapy Chemotherapy Drugs Infectious Mononucleosis Multiple Sclerosis Treatment and Modify Optic Neuritis Autoimmune Disorders Health Risks of Eating Pork 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive